Displaying 1 - 20 of 24
| Active Ingredient | AMANTADINE |
| Therapeutic Class | ADAMANTANES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIRETROVIRALS |
| Therapeutic Class | ANTIRETROVIRALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATAZANAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Theoretical risk of hyperbilirubinaemia in neonate if used at term. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DARUNAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RITONAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications |
Not typically used as sole protease inhibitor (PI), but as pharmacokinetic enhancer of other PIs Indicated in combination with other antiretroviral agents for the treatment of HIV-infection See lopin More ... |
| Caution | See lopinavir/ritonavir.Increased triglycerides, Diarrhea, Nausea , taste perversion, |
| Dose Range |
Initial dose 300mg twice daily gradually increased by 100mg twice daily over a period of up to 14 days to a maximum of 600mg twice daily . |
| Drug Interactions | |
| Pregnancy | See lopinavir/ritonavir. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | SAQUINAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | Treatment of HIV infection in combination with ritonavir and other antiretroviral agents. |
| Caution | Diarrhea, abdominal discomfort. |
| Dose Range | Adults and children (16 yrs of age and older): 1g twice daily with ritonavir 100mg twice daily , or with lop inavir 400mg/ritonavir 100mg twice daily . Administer within 2 hours after a meal. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DOLUTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ELVITEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | The fixed combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF) (EVG/c/FTC/TDF) is used for the treatment of human immunodeficiency virus type 1 (HIV More ... |
| Caution | Lactic acidosis and hepatomegaly with steatosis, including fatalities, have been reported with Tenofovir DF in combination with other antiretrovirals; risk is increased in women, obese patients, prolo More ... |
| Dose Range | Elvitegravir is often given with a protease inhibitor, a pharmacokinetic enhancer such as low-dose ritonavir, and at least one other antiretroviral drug; the dose may need to be adjusted to manage drug interactions. |
| Drug Interactions |
Drugs that induce these enzymes may decrease its plasma concentration and it should not be used with strong inducers of CYP3A which include the following: antibacterials (rifampicin) antidepressants More ... |
| Pregnancy | There are no or limited amount of data (less than 300 pregnancy outcomes) from t More ... |
| Breast Feeding | In order to avoid transmission of HIV to the infant it is recommended that HIV i More ... |
| Active Ingredient | RALTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EFAVIRENZ |
| Therapeutic Class | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI) |
| Indications |
In combination with other antiretrovirals for the treatment of HIV-1 infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that includ More ... |
| Caution | Psychiatric disorders, rash, increases in liver enzymes. |
| Dose Range |
Adult: 600mg once daily on an empty stomach preferably at bedtime. Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
| Drug Interactions | Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes. |
| Pregnancy | Efavirenz may cause fetal harm if administered during the first trimester of pre More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | NEVIRAPINE |
| Therapeutic Class | NNRTI |
| Indications | For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission. |
| Caution | Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson More ... |
| Dose Range | Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea |
| Drug Interactions | |
| Pregnancy | The human pregnancy data for nevirapine suggest that the risk for embryo–fetal h More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR |
| Therapeutic Class | NRTI |
| Indications |
Indicated in combination with other anti-HIV medications for the treatment of HIV-1 for adults and children. |
| Caution | Nausea, vomiting, fatigue, headache, diarrhoea and loss of appetite. Fatal lactic acidosis and severe hep atomegaly with steatosis have been reported. Fatal hypersensitivity reactions include s More ... |
| Dose Range | Adult: Recommended dosing is 300mg orally twice daily with or without food. Pediatric: 3 months - 16 years of age is 8mg/kg orally twice daily (up to a maximum of 300mg twice daily ). Abacavir should be used in combination with other antiretrovirals. |
| Drug Interactions | Alcohol reduces the metabolism of abacavir. |
| Pregnancy | The animal data suggest moderate risk. Although the human pregnancy experience d More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DIDANOSINE |
| Therapeutic Class | NRTI |
| Indications | A first-line component of a combination antiretroviral therapy regimenfor HIV-1 infected p atients. |
| Caution | Diarrhoea, neuropathy , chills or fever, rash, abdominal pain,weakness, headache and nausea/vomiting. Serious toxicities have included pancreatitis and lactic acidosis (which may be fata More ... |
| Dose Range | Adult: weighing greater than 60kg, 200mg twice daily . Weighing less than or equal to 60kg, 125mg twice daily . Pediatric 8 months and older: 120mg/square meter twice daily . 2 weeks - 8 months: 100mg/square meter twice daily . Take on an empty stomach. |
| Drug Interactions | Coadministration of Didanosine and allopurinol is contraindicated because systemic exposures of Didanosine are increased, which may increase Didanosine-associated toxicity |
| Pregnancy | Reproduction studies have been performed in rats and rabbits at doses up to 12 a More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LAMIVUDINE |
| Therapeutic Class | NRTI |
| Indications | A combination of oral lamivudine and oral zidovudine has p roduced significant and sustained increases in CD4+ counts and decreases in viral load in HIV-infected patients. Lamivudine is indicated for More ... |
| Caution | Diarrhoea, headache, fatigue, insomnia, arthralgias, myalgias, neuropathy, nasal signs and symptoms, elevated liver enzymes, skin rash, fever or chills, ear, nose and throat infections. Concurrent use More ... |
| Dose Range |
Adult: 150mg orally twice daily , or 300mg once daily . Pediatric 3 months - 16 years: 4mg/kg twice daily (up to a maximum dose of 150mg twice a day ). Chronic hep atitis B: 100mg orally daily for adults and 3mg/kg once daily (maximum daily dose = |
| Drug Interactions | |
| Pregnancy | The animal and human data suggest that lamivudine is a low risk to the developin More ... |
| Breast Feeding | Lamivudine is distributed into milk in humans. It is not known whether the drug More ... |
| Active Ingredient | STAVUDINE |
| Therapeutic Class | NRTI |
| Indications | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine p er tablet). Not recommended in children under 12 y ears. |
| Caution | Peripheral neuropathy , serum transaminase elevations, lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported. Concurrent administration of stavudine an More ... |
| Dose Range |
Adult greater than 60kg: 40mg every 12 hours and less than 60kg: 30mg every 12 hours. Pediatric: birth to 13 days: 0.5 mg/kg every 12 hours. 14 days and older: 1 mg/kg every 12 hours and weighing less than 30 kg. May be taken without regard to meals. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ZIDOVUDINE |
| Therapeutic Class | NRTI |
| Indications | In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, la More ... |
| Caution | Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincrist More ... |
| Dose Range | Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR | LAMIVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection in combination with other antiretrovirals. |
| Caution | As for abacavir and lamivudine. |
| Dose Range | Adult:40 kg and over One tablet once daily . Abacavir/Lamivudine can be taken with or without food. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATAZANAVIR | RITONAVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Ritonavir-Although the limited human data do not allow a better assessment of th More ... |
| Breast Feeding | Ritonavir-No reports describing the use of ritonavir during lactation have been More ... |
| Active Ingredient | BICTEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection. |
| Caution | Patients with HIV-1 infection should be tested for the presence of chronic hepatitis B virus (HBV) before initiating antiretroviral therapy (ART)Lactic acidosis and severe hepatomegaly with steatosis, More ... |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | COBICSTAT | ELVITEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV Infection |
| Caution | Appetite decreased; asthenia; constipation; diarrhoea; dizziness; electrolyte imbalance; flatulence; gastrointestinal discomfort; headache; hyperbilirubinaemia; hyperglycaemia; hypersensitivity; hyper More ... |
| Dose Range | 1 tablet once daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |